Bharat Biotech’s COVAXIN® Phase III data published in The Lancet

Bharat Biotech’s COVAXIN® Phase III data published in The Lancet Bharat Biotech, a global leader in vaccine development and innovation, announced today that the safety and efficacy analysis data from Phase III clinical trials of COVAXIN® is peer reviewed and published in The Lancet. https://ift.tt/eA8V8J